3-Ethyl-3-methyl-pentylamine | 137795-99-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Ethyl-3-methyl-pentylamine
• 英文别名: 3-Ethyl-3-methylpentan-1-amine
• CAS: 137795-99-4
• 化学式: C₈H₁₉N
• mdl: MFCD19210953
• 分子量: 129.246
• InChiKey: UILWQTLCRYJNPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Ethyl-3-methyl-pentylamine 在 palladium on activated charcoal sodium hydroxide 、 水 、 氢气 、 氯甲酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， -10.0~25.0 ℃ 、101.33 kPa 条件下， 反应 9.25h， 生成 (R)-4-(3-Chloro-benzoylamino)-4-(3-ethyl-3-methyl-pentylcarbamoyl)-butyric acid
  参考文献：
  名称：

  新的（R）-4-苯甲酰胺基-5-氧戊酸衍生物的结构-抗胃泌素活性关系。

  摘要：

  通过立体保守方法合成了新的（R）-4-benzamido-5-oxopentanoic酸衍生物，并在体外评估了其抑制[125I]（BH）-CCK-8与任一大鼠外周血（CCK-A）结合的能力）或中枢（CCK-B）CCK受体，或[3H] pentagastrin与兔胃腺的结合，以及在体内抑制五肽胃泌素在灌注的大鼠胃中输注所诱导的酸分泌。该系列的母体化合物（洛格米特）是CCK-A受体的第一种非肽类，有效和选择性拮抗剂。化学处理洛格鲁胺的结构导致发现CCK-B /胃泌素受体的选择性拮抗剂。讨论了构效关系。其中一些新衍生物与兔胃腺细胞和大鼠皮质膜表现出不同的亲和力，提示胃胃泌素受体（任意称为CCK-B1受体）与先前假设的与CCK中枢受体（称为CCK-B2）的关系不那么紧密。该系列中最有效的化合物，即（R）-4-（3,5-dichlorobenzamido）-5-（8-azaspiro [4.5] d

  DOI：

  10.1021/jm00079a003

文献信息

• Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
  申请人：UNOKI Gen

  公开号：US20090054472A1

  公开（公告）日：2009-02-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  式（1）所表示的吡唑并嘧啶衍生物及其药学上可接受的盐，表现出对MAPKAP-K2的优异抑制活性。因此，含有该化合物作为活性成分的药物预计将对由MAPKAP-K2介导的疾病具有治疗作用，例如，炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。
• PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：EP1780212A1

  公开（公告）日：2007-05-02

  The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

  式 I 所代表的吡唑并[1,5-a]嘧啶衍生物及其药学上可接受的盐类具有优异的 MAPKAP-K2 抑制活性。 因此，以这些化合物为有效成分的药物有望成为治疗或预防 MAPKAP-K2 介导的疾病（如炎症、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长）的药物。
• Antioxidant compounds and their use
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10858381B2

  公开（公告）日：2020-12-08

  Disclosed herein are novel amine-functionalized porphyrin compounds, as wells as pharmaceutically acceptable salts or esters thereof. The disclosed compounds can be used to impart antioxidant, anti-inflammatory, anti-microbial, and/or cell-adhesion specificity to a surface or material in need thereof, such as a surface of an indwelling medical implant, or a marine surface.

  本文公开了新型胺功能化卟啉化合物及其药学上可接受的盐或酯。所公开的化合物可用于向有需要的表面或材料（如留置医疗植入物表面或海洋表面）赋予抗氧化、抗炎、抗微生物和/或细胞粘附特异性。
• PROCESS FOR THE PREPARATION OF N-[(3-AMINOOXETAN-3-YL)METHYL]-2-(1,1-DIOXO-3,5-DIHYDRO-1,4-BENZOTHIAZEPIN-4-YL)-6-METHYL-QUINAZOLIN-4-AMINE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3097098B1

  公开（公告）日：2020-03-04
• Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus
  申请人：Tamada Sakuya

  公开号：US20060088786A1

  公开（公告）日：2006-04-27

  A rewritable optical information recording medium including a recording layer composed of an organic dye film is provided, in which recording and erasing information can be performed reversibly by laser light irradiation. A rewritable optical information recording medium including at least one organic dye film which is substantially made of only at least one kind of organic dye compounds as a recording film is provided. The recording and erasure of information are performed by a reversible physical change of the organic dye film substance caused by laser light irradiation. Specifically, data recording is performed by a physical change locally caused by the irradiation of recording laser light, data reproduction is performed by detecting change in intensity of returned light of reproducing laser light having less power than the recording laser light, and data erasure is performed by applying at least once continuous light or pulse light having laser power more than the reproducing laser light and less than the recording laser light. The physical change is a change in shape.